2,744 Shares in Axon Enterprise, Inc $AXON Bought by Landscape Capital Management L.L.C.

Key Points

• Landscape Capital Management invested approximately $1.44 million in Axon Enterprise, acquiring 2,744 shares, highlighting continued interest from institutional investors in the biotechnology company.
• Insider trading activities were reported, including the director purchasing 1,358 shares at an average price of $740, while the president sold 15,919 shares at an average price of $746.26.
• Axon Enterprise's quarterly earnings exceeded expectations with an EPS of $2.12, surpassing the analysts' consensus estimate of $1.54, and showing a year-over-year revenue increase of 32.6%.

Landscape Capital Management L.L.C. purchased a new position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,744 shares of the biotechnology company's stock, valued at approximately $1,443,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Kentucky Retirement Systems Insurance Trust Fund acquired a new position in Axon Enterprise in the first quarter valued at $1,110,000. Quotient Wealth Partners LLC purchased a new stake in shares of Axon Enterprise in the first quarter worth about $438,000. CX Institutional purchased a new stake in Axon Enterprise during the 1st quarter worth approximately $115,000. GAMMA Investing LLC grew its stake in Axon Enterprise by 11.8% in the first quarter. GAMMA Investing LLC now owns 1,454 shares of the biotechnology company's stock worth $765,000 after purchasing an additional 154 shares in the last quarter. Finally, DAVENPORT & Co LLC boosted its holdings in Axon Enterprise by 5.1% in the first quarter. DAVENPORT & Co LLC now owns 940 shares of the biotechnology company's stock worth $494,000 after purchasing an additional 46 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on AXON shares. Needham & Company LLC set a $870.00 price target on Axon Enterprise and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Wolfe Research initiated coverage on Axon Enterprise in a report on Monday, July 7th. They issued an "outperform" rating for the company. Craig Hallum raised Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price objective for the company in a report on Tuesday, August 5th. UBS Group reissued a "neutral" rating and issued a $840.00 price objective (up from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, Barclays increased their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Thirteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $837.69.

Insider Buying and Selling

In other Axon Enterprise news, Director Hadi Partovi bought 1,358 shares of Axon Enterprise stock in a transaction dated Wednesday, August 13th. The stock was bought at an average price of $740.00 per share, for a total transaction of $1,004,920.00. Following the completion of the acquisition, the director directly owned 237,938 shares of the company's stock, valued at approximately $176,074,120. This trade represents a 0.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction on Monday, August 11th. The shares were sold at an average price of $831.29, for a total value of $8,312,900.00. Following the completion of the sale, the chief executive officer owned 3,053,982 shares of the company's stock, valued at $2,538,744,696.78. The trade was a 0.33% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,703 shares of company stock valued at $31,366,051. 5.70% of the stock is currently owned by company insiders.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON traded down $3.70 on Tuesday, reaching $743.59. 493,576 shares of the company traded hands, compared to its average volume of 696,770. Axon Enterprise, Inc has a fifty-two week low of $346.71 and a fifty-two week high of $885.91. The company's 50 day moving average is $771.42 and its 200-day moving average is $677.75. The stock has a market capitalization of $58.37 billion, a PE ratio of 183.60, a P/E/G ratio of 27.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. During the same quarter in the prior year, the firm earned $1.20 EPS. The company's quarterly revenue was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.